Back to top
more

Calliditas Therapeutics (CALT)

(Delayed Data from NSDQ)

$18.65 USD

18.65
2,768

-0.85 (-4.35%)

Updated Apr 29, 2024 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

by Zacks Equity Research

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

by Zacks Equity Research

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.

Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

by Zacks Equity Research

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.

Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?

by Zacks Equity Research

Calliditas Therapeutics AB Sponsored ADR (CALT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

New Strong Sell Stocks for February 27th

by Zacks Equity Research

ATUS, CALT and CRC have been added to the Zacks Rank #5 (Strong Sell) List on February 27, 2023.

New Strong Sell Stocks for January 6th

by Zacks Equity Research

CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.

Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?

by Zacks Equity Research

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Can Calliditas Therapeutics AB Sponsored ADR (CALT) Climb 160% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 160.3% in Calliditas Therapeutics AB Sponsored ADR (CALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Calliditas Therapeutics AB Sponsored ADR (CALT)? Wall Street Analysts Think 200%

by Zacks Equity Research

The consensus price target hints at a 200.3% upside potential for Calliditas Therapeutics AB Sponsored ADR (CALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Calliditas' (CALT) Tarpeyo Wins FDA Approval for Renal Disease

by Zacks Equity Research

Calliditas (CALT) obtains accelerated approval for Tarpeyo to reduce proteinuria in IgA nephropathy in the United States.

Is a Surprise Coming for Calliditas (CALT) This Earnings Season?

by Zacks Equity Research

Calliditas (CALT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

National Vision (EYE) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.

What's in Store for Harrow Health (HROW) in Q2 Earnings?

by Zacks Equity Research

Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.

Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

by Zacks Equity Research

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.